2Ali Z.Al Minawi,Yin Fai Lee,et al.The ERCC1/XPF endonuclease is required for completion of homologous recombination at DNA replication forks stalled by inter-strand cress-links.Nucleic Acids Res,2009,37(19):6400.
3Abbasi R,Ramroth H,Becher H,et al.Polymorphisms of DNA repair genes and risk of non-small cell lung cancer.Carcinogenesis,2006,27(3):560.
4Hector.S,Bolanowska-Higdon W,Zdanowicz J,et al.In vitro studies on the mechanisms of oxaliplatin resistance.Cancer Chemother Pharmacol,2001,48(5):398.
5Arnould S,Hennebelle I,Canal P,et al.Cellular determinants of oxaliplatin sensitivity in colon cancer cell lines.Eur J Cancer,2003,39(1):112.
6Balin Ganthier D,Delord JP,Pillaire MJ,et al.Cetuximab potentiates oxaliplatin cytotoxic effect through a defect in NER and DNA replication initiation.Br J Cancer,2008,98(1):120.
7Paré L,Marcuello E,Altés A,et al.Pharmacogenetic prediction of clinical outcome in advanced colorectal cancer patients receiving oxaliplatin/5-fluorouracil as first-line chemotherapy.Br J Cancer,2008,99(7):1050.
8Kim SH,Kwou HE,Oh SY,et al.Prognostic value of ERCC1,thymidylate synthase,and glutathioue S-transferase pi for 5-FU/oxaliplatin chemotherapy in advanced colorectal cancer.Am J Clin Oncol,2009,32(1):38.
9Ruzzo A,Graziano F,Loupakis F,et al.Pharmacogenetic profiling in patients with advanced calorectal cancer treated with first-line FOLFOX-4 chemotherapy.Erratum in:J Clin Oncol,2009,27(19):3262.
10Park DJ,Zhang W,Stoehlmacher J,et al.ERCC1 gene polymorphism as a predictor for clinical outcome in advanced coloreetal cancer patients treated with platinum-based chemotherapy.Clin Adv Hematol Oncol,2003,1(3):162.
4Jemal A,Murray T,Samuels A,et al.Cancer statistics,2003.CA Cancer J Clin,2003,53(1):5-26.
5Goldberg RM,Tabah-Fisch I,Bleiberg H,et al.Pooled analysis of safety and efficacy of oxaliplatin plus fluorouracil/leucovorin administered bimonthly in elderly patients with colorectal cancer.J Clin Oncol,2006,24(25):4085-4091.
6Kouroussis C,Souglakos J,Kakolyris S,et al.Oxaliplatin in combination with infusional 5-fluorouracil and leucovorin every 2 weeks as first-line treatment in patients withadvanced colorectal cancer:a phase Ⅱ study.Oncology,2001,61 (1):36-41.
7Ahaha R, Liang X,Yu JJ, et al. Excision repair cross com- plementing-group l:gene expression and platinum resis- tance [J]. Int J Mol Med, 2004,14(6):959-970.
8Kurbacher CM, Cree IA, Bruckner HW, et al. Use of an ex vivo ATP luminescence assay to direct chemotherapy for recurrent ovarian cancer[J]. Anticancer Drugs, 1998, 9 (1):51-57.
9Su D,Ma S,Liu P,et al.Genetic polymorphisms and treat- ment response in advanced non-small cell lung cancer[J]. Lun Cancer, 2007, 56(2):281-288.
10Kawashima A,Nakayama M,Kakuta Y , et al. Excision re- pair cross-complementing group 1 may predict the efficacy of chemoradiation therapy for muscle-invasive bladder cancer[J]. Clin Cancer Res,2011, 17(8):2561-2569.
